- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
453
Companies which are more than 50% undervalued based on analyst price target.
453 companies
Dyne Therapeutics
Market Cap: US$1.8b
A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
DYN
US$12.65
7D
-4.1%
1Y
-63.6%
Celldex Therapeutics
Market Cap: US$1.7b
A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
CLDX
US$25.87
7D
6.8%
1Y
-20.2%
Immunocore Holdings
Market Cap: US$1.7b
A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
IMCR
US$36.33
7D
5.5%
1Y
16.4%
Edgewise Therapeutics
Market Cap: US$1.7b
A biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
EWTX
US$16.22
7D
7.5%
1Y
-40.6%
MannKind
Market Cap: US$1.7b
A biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.
MNKD
US$5.37
7D
0.4%
1Y
-14.2%
Vericel
Market Cap: US$1.6b
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
VCEL
US$31.47
7D
0.8%
1Y
-21.4%
Harmony Biosciences Holdings
Market Cap: US$1.6b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$27.56
7D
-14.1%
1Y
-29.8%
BioCryst Pharmaceuticals
Market Cap: US$1.6b
A biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.
BCRX
US$7.59
7D
-2.9%
1Y
2.8%
Biohaven
Market Cap: US$1.6b
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.
BHVN
US$15.01
7D
6.0%
1Y
-69.1%
Dianthus Therapeutics
Market Cap: US$1.5b
A clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
DNTH
US$39.35
7D
3.9%
1Y
41.1%
Structure Therapeutics
Market Cap: US$1.5b
A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
GPCR
US$28.00
7D
16.6%
1Y
-33.6%
AbCellera Biologics
Market Cap: US$1.5b
Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
ABCL
US$5.03
7D
2.7%
1Y
95.7%
Janux Therapeutics
Market Cap: US$1.4b
A clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer.
JANX
US$24.44
7D
6.4%
1Y
-45.1%
Arcus Biosciences
Market Cap: US$1.4b
A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
RCUS
US$13.60
7D
9.8%
1Y
-11.8%
Ardelyx
Market Cap: US$1.4b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.51
7D
-10.4%
1Y
-19.6%
Syndax Pharmaceuticals
Market Cap: US$1.3b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$15.39
7D
3.6%
1Y
-22.6%
Rapport Therapeutics
Market Cap: US$1.3b
Operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
RAPP
US$29.70
7D
11.4%
1Y
46.2%
Enliven Therapeutics
Market Cap: US$1.2b
A clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
ELVN
US$20.47
7D
6.7%
1Y
-21.3%
Atai Life Sciences
Market Cap: US$1.2b
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
ATAI
US$5.29
7D
-5.7%
1Y
372.3%
Innoviva
Market Cap: US$1.2b
Engages in the development and commercialization of pharmaceutical products in the United States and internationally.
INVA
US$18.25
7D
-3.6%
1Y
-6.7%
Wave Life Sciences
Market Cap: US$1.1b
A clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
WVE
US$7.32
7D
7.2%
1Y
-11.8%
Dynavax Technologies
Market Cap: US$1.1b
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
DVAX
US$9.93
7D
3.5%
1Y
-12.1%
ORIC Pharmaceuticals
Market Cap: US$1.1b
A clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States.
ORIC
US$12.00
7D
14.5%
1Y
19.5%
Nektar Therapeutics
Market Cap: US$1.1b
A biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
NKTR
US$56.90
7D
-4.5%
1Y
191.8%
Praxis Precision Medicines
Market Cap: US$1.1b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
PRAX
US$53.00
7D
9.1%
1Y
-7.7%
Nuvation Bio
Market Cap: US$1.1b
A clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology.
NUVB
US$3.70
7D
14.9%
1Y
60.9%
Trevi Therapeutics
Market Cap: US$1.1b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
TRVI
US$9.15
7D
9.2%
1Y
194.2%
Precigen
Market Cap: US$1.1b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$3.29
7D
-11.3%
1Y
247.7%
MiMedx Group
Market Cap: US$1.0b
Develops and distributes placental tissue allografts for various sectors of healthcare.
MDXG
US$6.98
7D
-1.8%
1Y
18.3%
Spyre Therapeutics
Market Cap: US$1.0b
A clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
SYRE
US$16.76
7D
-1.4%
1Y
-39.5%
Immunome
Market Cap: US$987.1m
A clinical-stage biotechnology company, develops targeted cancer therapies.
IMNM
US$11.71
7D
10.9%
1Y
-13.4%
EyePoint Pharmaceuticals
Market Cap: US$968.4m
Engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
EYPT
US$14.24
7D
6.3%
1Y
78.0%
Immatics
Market Cap: US$961.5m
A clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
IMTX
US$8.52
7D
19.7%
1Y
-24.0%
ARS Pharmaceuticals
Market Cap: US$960.6m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$10.05
7D
1.1%
1Y
-30.5%
Upstream Bio
Market Cap: US$934.8m
A clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
UPB
US$18.81
7D
15.5%
1Y
n/a
Sana Biotechnology
Market Cap: US$927.7m
A biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
SANA
US$3.55
7D
8.9%
1Y
-16.3%